Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
2.
J Clin Psychiatry ; 59(4): 184-8, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9590669

ABSTRACT

BACKGROUND: A potential beneficial outcome of treatment with certain of the atypical neuroleptics is the reduced risk of cognitive impairment, stemming from purported low affinity for cholinergic receptors. In vitro experiments have shown that clozapine is highly anticholinergic and risperidone is minimally so. In vivo tests of the anticholinergic burden imposed by these medications and its potential cognitive consequences are needed. This study examines anticholinergic burden in schizophrenia patients taking clozapine and risperidone and tests whether this burden is associated with cognitive deficits. METHOD: Serum anticholinergic levels were determined in a sample of 22 chronic schizophrenia patients using the radioreceptor assay method of Tune and Coyle (1980). Fifteen patients received clozapine; 7 received risperidone. Mean +/- SD age of the sample, comprising 12 men and 10 women (68% white), was 44.7 +/- 8.4 years. Mean +/- SD age at onset of schizophrenia illness was 23.5 +/- 7.4 years. Two anticholinergic assays based on blood samples collected 1 week apart were available on each patient. RESULTS: Data indicated that clozapine patients had significantly (p < .001) higher anticholinergic levels at both collection points, and levels for both drugs remained stable over time. The clozapine and risperidone patients had essentially equivalent scores on the cognitive measure. CONCLUSION: These data suggest that anticholinergicity distinguishes clozapine and risperidone in vivo but that this effect is not associated with differences in global cognitive functioning. Results suggest that clozapine, despite producing moderately high in vivo serum anticholinergic levels, still holds clinical advantage over standard neuroleptics in terms of cognitive side effects. Reasons for this lowered risk of cognitive impairment are discussed.


Subject(s)
Cholinergic Antagonists/pharmacology , Clozapine/pharmacology , Clozapine/therapeutic use , Cognition Disorders/chemically induced , Risperidone/pharmacology , Risperidone/therapeutic use , Schizophrenia/drug therapy , Adult , Cognition Disorders/blood , Female , Humans , Male , Middle Aged , Muscarinic Antagonists/blood , Muscarinic Antagonists/metabolism , Psychiatric Status Rating Scales , Quinuclidinyl Benzilate/metabolism , Radioligand Assay , Receptors, Cholinergic/blood , Receptors, Cholinergic/drug effects , Schizophrenia/blood , Schizophrenia/diagnosis , Schizophrenic Psychology , Tritium
3.
Ann Ital Chir ; 68(6): 819-22, 1997.
Article in Italian | MEDLINE | ID: mdl-9646543

ABSTRACT

In recent years we are observing an increasing number of authors. The surgical results, in the elective cases, are improved drammatically, and now, in many Centers, the mortality rate is less than 5%. We haven't observed the same improvements for the emergency cases. In this setting the mortality rate is still around 50% or more. What we are facing, however, is the changing of the clinical picture of this patients. In the most part of cases, the patient dies in the Intensive Care Unit, after a long and complex post-operative course, and not more in the Operating Room. Still, this could be considered a good result, expression of a better surgical experience. The way to obtain higher survival, at the moment, is linked to a better understanding of the physiologic derangements in the Intensive Care Unit. The authors discuss the organizative and technical changes the permitted to achieve this results.


Subject(s)
Aortic Aneurysm, Abdominal/surgery , Aortic Rupture/surgery , Vascular Surgical Procedures/methods , Aged , Aged, 80 and over , Aortic Aneurysm, Abdominal/complications , Aortic Aneurysm, Abdominal/mortality , Aortic Rupture/complications , Aortic Rupture/mortality , Female , Humans , Male , Middle Aged , Vascular Surgical Procedures/mortality
4.
Schizophr Res ; 22(2): 103-9, 1996 Nov 15.
Article in English | MEDLINE | ID: mdl-8958593

ABSTRACT

Estimating premorbid intelligence in schizophrenia is difficult because the illness affects aspects of premorbid and postmorbid functioning. We evaluated two qualitatively different estimates of premorbid intelligence in a sample of schizophrenia patients and tested whether: (1) the two indices were related and produced similar IQ estimates, and (2) either index was related to a measure of cognitive deterioration. The Barona Index (BI, a demographically-based instrument) and the National Adult Reading Test (NART, a reading test of irregularly-spelled words) were utilized. Subjects (n = 40) were adult neuroleptic-medicated inpatients with a DSM-III-R diagnosis of chronic schizophrenia (n = 35) or schizoaffective disorder (n = 5). Paired t-tests revealed statistically equivalent BI and NART estimates for Full Scale and Verbal IQs, but significantly higher NART Performance IQs (t[35] = -3.34, p < 0.01). Correlational analyses suggested the two indices were associated but shared modest variance. BI correlations revealed expected associations with education and social position. NART IQs were related to education and a measure of cognitive status. Regression analyses supported the association between NART estimates and cognitive deterioration. Results suggest BI may be a better estimate of premorbid intelligence in schizophrenia as it is less influenced by potential consequences of the disease.


Subject(s)
Intelligence , Reading , Schizophrenia/diagnosis , Schizophrenic Psychology , Schizotypal Personality Disorder/diagnosis , Adult , Chronic Disease , Cognition Disorders/diagnosis , Cognition Disorders/psychology , Female , Humans , Male , Mental Status Schedule , Middle Aged , Psychotic Disorders/diagnosis , Psychotic Disorders/psychology , Schizotypal Personality Disorder/psychology
7.
Am J Cardiol ; 57(7): 30D-34D, 1986 Feb 26.
Article in English | MEDLINE | ID: mdl-3953427

ABSTRACT

The effects of a single large dose of verapamil on left ventricular (LV) function were evaluated noninvasively in 18 chronically hypertensive patients. Each patient was given a single oral dose of verapamil, 240 mg, before and after which arterial blood pressure was measured and an echocardiogram and a phonomechanocardiogram were obtained. Reactional symmetrical myocardial hypertrophy was seen in all patients on the first echocardiogram. Results showed that heart rate was not significantly altered, but there were significant decreases (p less than 0.01) in systolic blood pressure (183.89 to 127.56 mm Hg) and diastolic blood pressure (101.11 to 77.67 mm Hg). The following parameters were also significantly decreased (p less than 0.01): LV ejection time (294.56 to 274.22 ms), LV diastolic diameter (45.78 to 43.99 mm), percentage change in LV diameter (33 to 27.83%), mean velocity of circumferential fiber shortening (1.12 to 1.02 cir/s), posterior wall contraction velocity (40.83 to 36.28 mm/s), LV end-diastolic volume (97.78 to 86.89 cm3), ejection fraction (0.70 to 0.62), stroke volume (70 to 55 cm3) and cardiac output (4.7 to 4 liters/m). Three parameters were significantly increased (p less than 0.01): preejection period (104.06 to 112.06 ms), preejection period: LV ejection time ratio (0.35 to 0.41) and end-systolic volume (29.28 to 32.33 cm3). It is concluded that a single oral dose of verapamil, 240 mg, is highly efficient in lowering arterial blood pressure in chronically hypertensive patients and in reducing the peripheral resistance and LV performance indexes.


Subject(s)
Heart/drug effects , Hypertension/drug therapy , Verapamil/therapeutic use , Administration, Oral , Adult , Aged , Blood Pressure/drug effects , Cardiac Output/drug effects , Drug Evaluation , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Myocardial Contraction/drug effects , Stroke Volume/drug effects , Verapamil/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...